{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:43:57Z","timestamp":1785811437967,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Associazione Italiana Ricerca sul Cancro (AIRC),\u00a0AIRC 5X1000","award":["AIRC-ISM ID 21147"],"award-info":[{"award-number":["AIRC-ISM ID 21147"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02191-7","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:34:48Z","timestamp":1780119288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of allogeneic hematopoietic stem cell transplantation in patients with blast phase myelofibrosis: molecular signature and intensive chemotherapy matter"],"prefix":"10.1007","volume":"26","author":[{"given":"Francesca","family":"Valsecchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Finazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Salmoiraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pavoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Algarotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Bellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Frigeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Condorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Rizzuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Cavallaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Belotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Milani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orietta","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Lussana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"2191_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/AJH.26857","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Primary myelofibrosis. 2023 update on diagnosis, risk-stratification, and management. Am J Hematol Am J Hematol. 2023;98:801\u201321. https:\/\/doi.org\/10.1002\/AJH.26857.","journal-title":"Am J Hematol Am J Hematol"},{"key":"2191_CR2","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/BLOOD.2022017423","volume":"141","author":"F Passamonti","year":"2023","unstructured":"Passamonti F, Mora B, Myelofibrosis. Blood Am Soc Hematol. 2023;141:1954\u201370. https:\/\/doi.org\/10.1182\/BLOOD.2022017423.","journal-title":"Blood Am Soc Hematol"},{"key":"2191_CR3","doi-asserted-by":"publisher","unstructured":"Tefferi A, Alkhateeb H, Gangat N. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm. Blood Cancer Journal 2023 13:1. Nature Publishing Group; 2023;13:1\u201311. https:\/\/doi.org\/10.1038\/s41408-023-00878-8","DOI":"10.1038\/s41408-023-00878-8"},{"key":"2191_CR4","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/J.LEUKRES.2006.12.002","volume":"31","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and. Leuk Res Pergamon. 2007;31:737\u201340. https:\/\/doi.org\/10.1016\/J.LEUKRES.2006.12.002.","journal-title":"Leuk Res Pergamon"},{"key":"2191_CR5","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328. https:\/\/doi.org\/10.1182\/blood.2022015850.","journal-title":"Blood"},{"key":"2191_CR6","doi-asserted-by":"publisher","unstructured":"Mesa RA, Li C-Y, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. 2005; https:\/\/doi.org\/10.1182\/blood-2004-07-2864","DOI":"10.1182\/blood-2004-07-2864"},{"key":"2191_CR7","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Mudireddy M, Mannelli F, Begna KH, Patnaik MM, Hanson CA, et al. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia 2018 32:5. Nat Publishing Group. 2018;32:1200\u201310. https:\/\/doi.org\/10.1038\/s41375-018-0019-y.","journal-title":"Nat Publishing Group"},{"key":"2191_CR8","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.3324\/HAEMATOL.2022.282627","volume":"108","author":"MG Abdelmagid","year":"2023","unstructured":"Abdelmagid MG, Al-Kali A, Begna KH, Hogan WJ, Litzow MR, Fleti F, et al. Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival. Haematol Haematol. 2023;108:2542\u20135. https:\/\/doi.org\/10.3324\/HAEMATOL.2022.282627.","journal-title":"Haematol Haematol"},{"key":"2191_CR9","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1182\/BLOODADVANCES.2024012880","volume":"8","author":"AA Patel","year":"2024","unstructured":"Patel AA, Yoon JJ, Johnston H, Davidson MB, Shallis RM, Chen EC, et al. Treatment approach and outcomes of patients with accelerated\/blast-phase myeloproliferative neoplasms in the current era. Blood Adv Content Repository Only! 2024;8:3468\u201377. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2024012880.","journal-title":"Blood Adv Content Repository Only!"},{"key":"2191_CR10","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3324\/HAEMATOL.2013.094284","volume":"99","author":"F Lussana","year":"2014","unstructured":"Lussana F, Rambaldi A, Finazzi MC, van Biezen A, Scholten M, Oldani E, et al. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the. Haematol Haematol. 2014;99:916\u201321. https:\/\/doi.org\/10.3324\/HAEMATOL.2013.094284.","journal-title":"Haematol Haematol"},{"key":"2191_CR11","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/BJH.15819","volume":"185","author":"N Kr\u00f6ger","year":"2019","unstructured":"Kr\u00f6ger N, Eikema DJ, K\u00f6ster L, Beelen D, de Wreede LC, Finke J, et al. Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia. Br J Haematol Br J Haematol. 2019;185:725\u201332. https:\/\/doi.org\/10.1111\/BJH.15819.","journal-title":"Br J Haematol Br J Haematol"},{"key":"2191_CR12","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.1182\/BLOODADVANCES.2020002621","volume":"4","author":"V Gupta","year":"2020","unstructured":"Gupta V, Kim S, Hu ZH, Liu Y, Aljurf M, Bacher U, et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1\u2009\u2013\u2009MPN with de novo AML and with AML following MDS. Blood Adv Am Soc Hematol. 2020;4:4748\u201357. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2020002621.","journal-title":"Blood Adv Am Soc Hematol"},{"key":"2191_CR13","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/AJH.26833","volume":"98","author":"G Ort\u00ed","year":"2023","unstructured":"Ort\u00ed G, Gras L, Zinger N, Finazzi MC, Sockel K, Robin M, et al. Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol Am J Hematol. 2023;98:628\u201338. https:\/\/doi.org\/10.1002\/AJH.26833.","journal-title":"Am J Hematol Am J Hematol"},{"key":"2191_CR14","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/BJH.17423","volume":"193","author":"MV Shah","year":"2021","unstructured":"Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, et al. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol [Internet] Br J Haematol. 2021;193:1004\u20138. https:\/\/doi.org\/10.1111\/BJH.17423. [cited 2026 Apr 21];.","journal-title":"Br J Haematol [Internet] Br J Haematol"},{"key":"2191_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/J.BBMT.2009.12.004","volume":"16","author":"SO Ciurea","year":"2010","unstructured":"Ciurea SO, de Lima M, Giralt S, Saliba R, Bueso-Ramos C, Andersson BS, et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transpl Biol Blood Marrow Transpl. 2010;16:555\u20139. https:\/\/doi.org\/10.1016\/J.BBMT.2009.12.004.","journal-title":"Biol Blood Marrow Transpl Biol Blood Marrow Transpl"},{"key":"2191_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/J.BBMT.2013.10.027","volume":"20","author":"H Alchalby","year":"2014","unstructured":"Alchalby H, Zabelina T, St\u00fcbig T, van Biezen A, Bornh\u00e4user M, Di Bartolomeo P, et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. Biol Blood Marrow Transpl. 2014;20:279\u201381. https:\/\/doi.org\/10.1016\/J.BBMT.2013.10.027.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2191_CR17","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/J.BBMT.2016.08.029","volume":"22","author":"A Keyzner","year":"2016","unstructured":"Keyzner A, Han S, Shapiro S, Moshier E, Schorr E, Petersen B, et al. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis. Biol Blood Marrow Transplant. Biol Blood Marrow Transpl. 2016;22:2180\u20136. https:\/\/doi.org\/10.1016\/J.BBMT.2016.08.029.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2191_CR18","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leuk Springer US. 2022;36:1703\u201319. https:\/\/doi.org\/10.1038\/s41375-022-01613-1.","journal-title":"Leuk Springer US"},{"key":"2191_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377. https:\/\/doi.org\/10.1182\/blood.2022016867.","journal-title":"Blood"},{"key":"2191_CR20","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/J.BBMT.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. Biol Blood Marrow Transpl. 2009;15:1628\u201333. https:\/\/doi.org\/10.1016\/J.BBMT.2009.07.004.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2191_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.001","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, International, International Consortium. Biol Blood Marrow Transplant. 2016;22:4\u201310. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.001. Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD."},{"key":"2191_CR22","doi-asserted-by":"publisher","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biology of Blood and Marrow Transplantation. Volume 21. Elsevier Inc; 2015. pp. 389\u2013e4011. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001.","DOI":"10.1016\/j.bbmt.2014.12.001"},{"key":"2191_CR23","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41409-024-02251-0","volume":"59","author":"A Sureda","year":"2024","unstructured":"Sureda A, Carpenter PA, Bacigalupo A, Bhatt VR, de la Fuente J, Ho A, et al. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. Bone Marrow Transpl Springer US. 2024;59:832\u20137. https:\/\/doi.org\/10.1038\/s41409-024-02251-0.","journal-title":"Bone Marrow Transpl Springer US"},{"key":"2191_CR24","doi-asserted-by":"publisher","unstructured":"Introna M, Lussana F, Algarotti A, Gotti E, Valgardsdottir R, Mic\u00f2 C et al. Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation [Internet]. Elsevier Inc.; 2017 [cited 2026 Mar 19];23:2070\u20138. https:\/\/doi.org\/10.1016\/j.bbmt.2017.07.005","DOI":"10.1016\/j.bbmt.2017.07.005"},{"key":"2191_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01376-9","author":"MC Finazzi","year":"2025","unstructured":"Finazzi MC, Salmoiraghi S, Valsecchi F, Pavoni C, Belotti C, Grassi A, et al. The number of additional high molecular risk mutations predicts outcome after hematopoietic stem cell transplantation in primary and secondary myelofibrosis. Blood Cancer J Springer Nat. 2025. https:\/\/doi.org\/10.1038\/s41408-025-01376-9.","journal-title":"Blood Cancer J Springer Nat"},{"key":"2191_CR26","doi-asserted-by":"publisher","unstructured":"Craddock C, Mcllroy G, Vincent H, Smith G, Johnson S, Collings R, et al. Addition of thiotepa to a busulphan based conditioning regimen does not improve survival in patients allografted for acute myeloid leukaemia and myelodysplasia: Results of the UK impact cosi trial. Blood [Internet]. Volume 146. American Society of Hematology; 2025. pp. 110\u2013110. [cited 2026 Mar 19]. https:\/\/doi.org\/10.1182\/blood-2025-110.","DOI":"10.1182\/blood-2025-110"},{"key":"2191_CR27","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","volume":"11","author":"N Kr\u00f6ger","year":"2024","unstructured":"Kr\u00f6ger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group. Lancet Haematol. 2024;11:e62\u201374. https:\/\/doi.org\/10.1016\/S2352-3026(23)00305-8.","journal-title":"Lancet Haematol"},{"key":"2191_CR28","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.3324\/HAEMATOL.2022.282019","volume":"108","author":"N Gangat","year":"2023","unstructured":"Gangat N, Ilyas R, McCullough K, Begna KH, Al-Kali A, Patnaik MM, et al. Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm. Haematol Ferrata Storti Foundation. 2023;108:1423\u20138. https:\/\/doi.org\/10.3324\/HAEMATOL.2022.282019.","journal-title":"Haematol Ferrata Storti Foundation"},{"key":"2191_CR29","doi-asserted-by":"publisher","unstructured":"Vannucchi A, Mannelli F, Crupi F, Caroprese J, Lomi M, Enderti A et al. Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial. Blood [Internet]. Content Repository Only! 2025 [cited 2026 Mar 27];146:1025. https:\/\/doi.org\/10.1182\/blood-2025-1025","DOI":"10.1182\/blood-2025-1025"},{"key":"2191_CR30","doi-asserted-by":"publisher","unstructured":"Chiusolo P, Bregante S, Giammarco S, Lamparelli T, Casarino L, Dominietto A et al. Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen. Am J Hematol. John Wiley & Sons, Ltd; 2021;96:234\u201340. https:\/\/doi.org\/10.1002\/AJH.26042","DOI":"10.1002\/AJH.26042"},{"key":"2191_CR31","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1182\/BLOOD.2023019630","volume":"141","author":"N Gagelmann","year":"2023","unstructured":"Gagelmann N, Badbaran A, Salit RB, Schroeder T, Gurnari C, Pagliuca S, et al. Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood Am Soc Hematol. 2023;141:2901\u201311. https:\/\/doi.org\/10.1182\/BLOOD.2023019630.","journal-title":"Blood Am Soc Hematol"},{"key":"2191_CR32","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1182\/BLOOD.2023021349","volume":"143","author":"I Crespiatico","year":"2024","unstructured":"Crespiatico I, Zaghi M, Mastini C, D\u2019Aliberti D, Mauri M, Mercado CM, et al. First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. Blood Blood. 2024;143:1399\u2013413. https:\/\/doi.org\/10.1182\/BLOOD.2023021349.","journal-title":"Blood Blood"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02191-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02191-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02191-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:45:45Z","timestamp":1785807945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02191-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2191"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02191-7","relation":{"references":[{"id-type":"doi","id":"10.1016\/j.bbmt.2015.09.001","asserted-by":"subject"}]},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients included in this study signed an informed consent form, which allowed their data to be transferred to the national competent authority, the EBMT (European Bone Marrow Transplantation) Registry, and to be used for scientific purposes. This study was conducted following the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"290"}}